ONCODESIGN PRECISION MEDICIN (ALOPM.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALOPM - FR001400CM63 - Common Stock
ALOPM.PA Key Statistics, Chart & Performance
The current stock price of ALOPM.PA is 0.479 EUR. In the past month the price increased by 18.27%. In the past year, price decreased by -29.56%.
ALOPM.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 66.13 | 43.32B | ||
| ARGX.BR | ARGENX SE | 65.51 | 42.91B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.53B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.59B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.74B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.86B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.87B | ||
| NANO.PA | NANOBIOTIX | N/A | 841.84M | ||
| 5CV.DE | CUREVAC NV | 6.71 | 876.36M | ||
| IVA.PA | INVENTIVA SA | N/A | 779.35M | ||
| 6IV.DE | INVENTIVA SA | N/A | 753.57M | ||
| PHIL.MI | PHILOGEN SPA | 20 | 666.67M |
Related stock screener links
About ALOPM.PA
Company Profile
Oncodesign Precision Medicine (OPM) SAS manufactures precision medicine. The company is headquartered in Dijon, Bourgogne-Franche-Comte and currently employs 13 full-time employees. The company went IPO on 2022-10-05. The company aims at providing effective diagnostic and therapeutic solutions for resistant and metastatic cancers. The Company’s technologies from Oncodesign, are OncoSNIPER for the selection of therapeutic targets using artificial intelligence; Nanocyclix for the design and selection of macrocyclic small molecule kinase inhibitors and Theranostics for the design and selection of radiolabeled biological molecules for systemic radiotherapy. The company focuses on the research and development of therapeutic and diagnostic solutions in the clinical and preclinical areas of medical oncology.
Company Info
ONCODESIGN PRECISION MEDICIN
18 Rue Jean Mazen
Dijon BOURGOGNE-FRANCHE-COMTE FR
Employees: 18
ONCODESIGN PRECISION MEDICIN / ALOPM.PA FAQ
What does ONCODESIGN PRECISION MEDICIN do?
Oncodesign Precision Medicine (OPM) SAS manufactures precision medicine. The company is headquartered in Dijon, Bourgogne-Franche-Comte and currently employs 13 full-time employees. The company went IPO on 2022-10-05. The company aims at providing effective diagnostic and therapeutic solutions for resistant and metastatic cancers. The Company’s technologies from Oncodesign, are OncoSNIPER for the selection of therapeutic targets using artificial intelligence; Nanocyclix for the design and selection of macrocyclic small molecule kinase inhibitors and Theranostics for the design and selection of radiolabeled biological molecules for systemic radiotherapy. The company focuses on the research and development of therapeutic and diagnostic solutions in the clinical and preclinical areas of medical oncology.
What is the stock price of ONCODESIGN PRECISION MEDICIN today?
The current stock price of ALOPM.PA is 0.479 EUR.
Does ONCODESIGN PRECISION MEDICIN pay dividends?
ALOPM.PA does not pay a dividend.
How is the ChartMill rating for ONCODESIGN PRECISION MEDICIN?
ALOPM.PA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for ONCODESIGN PRECISION MEDICIN?
ONCODESIGN PRECISION MEDICIN (ALOPM.PA) operates in the Health Care sector and the Biotechnology industry.
Can you provide the growth outlook for ONCODESIGN PRECISION MEDICIN?
The Revenue of ONCODESIGN PRECISION MEDICIN (ALOPM.PA) is expected to grow by 151.06% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for ONCODESIGN PRECISION MEDICIN?
ONCODESIGN PRECISION MEDICIN (ALOPM.PA) currently has 18 employees.
ALOPM.PA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ALOPM.PA. When comparing the yearly performance of all stocks, ALOPM.PA is a bad performer in the overall market: 88.85% of all stocks are doing better.
ALOPM.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALOPM.PA. ALOPM.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
ALOPM.PA Financial Highlights
Over the last trailing twelve months ALOPM.PA reported a non-GAAP Earnings per Share(EPS) of -0.3. The EPS increased by 18.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.18% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALOPM.PA Forecast & Estimates
9 analysts have analysed ALOPM.PA and the average price target is 2.04 EUR. This implies a price increase of 325.89% is expected in the next year compared to the current price of 0.479.
For the next year, analysts expect an EPS growth of 95% and a revenue growth 151.06% for ALOPM.PA